Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 8—August 2005


Cost-Benefit of Stockpiling Drugs for Influenza Pandemic

Ran D. Balicer*†Comments to Author , Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Author affiliations: *Ministry of Health, Jerusalem, Israel; †Ben-Gurion University of the Negev, Be'er-Sheva, Israel

Main Article

Table A4

Preexposure (seasonal) prophylaxis trials included in the analysis

Trial Age group, y Intervention (no. participants) Treatment duration
Hayden et al., 1999 (11) 18–65 Oseltamivir 75 mg 1×/d (520) 6 weeks
Oseltamivir 75 mg 2×/d (520)
Placebo (519)
Monto et al., 1999 (15) 18–69 Zanamivir 10 mg 1×/d (553) 4 weeks
Placebo (554)

Main Article